SANTA CLARA, Calif.–(BUSINESS WIRE)–PercAssist, Inc., a medical device company developing innovative technology for extravascular Biventricular Mechanical Circulatory Support to provide hemodynamic improvements for patients in cardiogenic shock (CS), today announced the first patient enrollment for the AVANXA Feasibility Study was successfully conducted in São Paulo, Brazil. “I am thrilled to share the successful clinical use of the PercAssist eVAD System in a patient with SCAI Stage D CS,” s
See full post here as originally published on this site
